HCM
TEVA icon

Highbridge Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Highbridge Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000,000
Closed -$15.4M – 427
2018
Q4 		$15.4M Hold
1,000,000
– – 0.46% 66
2018
Q3 		$21.5M Hold
1,000,000
– – 0.51% 47
2018
Q2 		$24.3M Hold
1,000,000
– – 0.49% 46
2018
Q1 		$17.1M Hold
1,000,000
– – 0.28% 75
2017
Q4 		$18.9M Hold
1,000,000
– – 0.34% 58
2017
Q3 		$17.6M Buy
+1,000,000
New +$22.5M 0.26% 98

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's TEVA Position: Q4 2016 in Review

Highbridge Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 384,269 shares — an estimated $17.7M sold.

Highbridge Capital Management first reported a position in TEVA in Q3 2016 and held it in 1 quarter. The position peaked at $17.7M in Q3 2016. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Highbridge Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 384,269 Teva Pharmaceuticals shares in Q4 2016, an estimated $17.7M.
  • Highbridge Capital Management first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Highbridge Capital Management's Teva Pharmaceuticals position peaked at $17.7M in Q3 2016.
  • 738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.